AU2020480841A1 - Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification - Google Patents
Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification Download PDFInfo
- Publication number
- AU2020480841A1 AU2020480841A1 AU2020480841A AU2020480841A AU2020480841A1 AU 2020480841 A1 AU2020480841 A1 AU 2020480841A1 AU 2020480841 A AU2020480841 A AU 2020480841A AU 2020480841 A AU2020480841 A AU 2020480841A AU 2020480841 A1 AU2020480841 A1 AU 2020480841A1
- Authority
- AU
- Australia
- Prior art keywords
- retinal
- eye
- light
- retina
- idm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002207 retinal effect Effects 0.000 title claims abstract description 568
- 238000000034 method Methods 0.000 title claims abstract description 294
- 230000004438 eyesight Effects 0.000 title claims abstract description 124
- 230000004048 modification Effects 0.000 title claims abstract description 97
- 238000012986 modification Methods 0.000 title claims abstract description 97
- 238000004017 vitrification Methods 0.000 title claims description 7
- 238000009826 distribution Methods 0.000 title description 40
- 230000007613 environmental effect Effects 0.000 claims abstract description 149
- 230000004287 retinal location Effects 0.000 claims abstract description 87
- 230000002441 reversible effect Effects 0.000 claims abstract description 23
- 210000001525 retina Anatomy 0.000 claims description 151
- 210000004087 cornea Anatomy 0.000 claims description 122
- 210000004027 cell Anatomy 0.000 claims description 112
- 230000003287 optical effect Effects 0.000 claims description 78
- 230000006735 deficit Effects 0.000 claims description 15
- 230000002787 reinforcement Effects 0.000 claims description 14
- 230000009466 transformation Effects 0.000 claims description 11
- 238000005259 measurement Methods 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 10
- 238000000059 patterning Methods 0.000 claims description 8
- 230000004377 improving vision Effects 0.000 claims description 6
- 230000000007 visual effect Effects 0.000 abstract description 130
- 230000004393 visual impairment Effects 0.000 abstract description 27
- 230000001537 neural effect Effects 0.000 abstract description 20
- 230000001052 transient effect Effects 0.000 abstract description 15
- 230000010354 integration Effects 0.000 abstract description 12
- 230000008447 perception Effects 0.000 abstract description 12
- 230000000638 stimulation Effects 0.000 abstract description 5
- 208000029257 vision disease Diseases 0.000 abstract description 3
- 206010047571 Visual impairment Diseases 0.000 abstract description 2
- 238000005070 sampling Methods 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 description 315
- 238000011282 treatment Methods 0.000 description 93
- 210000000695 crystalline len Anatomy 0.000 description 87
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
- 206010064930 age-related macular degeneration Diseases 0.000 description 36
- 230000007423 decrease Effects 0.000 description 35
- 108091008695 photoreceptors Proteins 0.000 description 34
- 208000022873 Ocular disease Diseases 0.000 description 33
- 230000006872 improvement Effects 0.000 description 33
- 230000008569 process Effects 0.000 description 33
- 230000006399 behavior Effects 0.000 description 30
- 230000003247 decreasing effect Effects 0.000 description 29
- 238000012545 processing Methods 0.000 description 29
- 230000006378 damage Effects 0.000 description 25
- 208000035475 disorder Diseases 0.000 description 25
- 208000008069 Geographic Atrophy Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 208000017442 Retinal disease Diseases 0.000 description 21
- 208000002780 macular degeneration Diseases 0.000 description 21
- 230000002123 temporal effect Effects 0.000 description 21
- 208000003098 Ganglion Cysts Diseases 0.000 description 20
- 208000005400 Synovial Cyst Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 230000035945 sensitivity Effects 0.000 description 20
- 230000004304 visual acuity Effects 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 230000008439 repair process Effects 0.000 description 17
- 201000004569 Blindness Diseases 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- 206010012689 Diabetic retinopathy Diseases 0.000 description 15
- 208000010412 Glaucoma Diseases 0.000 description 15
- 229920001436 collagen Polymers 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 239000004973 liquid crystal related substance Substances 0.000 description 15
- 230000009286 beneficial effect Effects 0.000 description 14
- 238000002679 ablation Methods 0.000 description 13
- 230000002093 peripheral effect Effects 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 230000003565 oculomotor Effects 0.000 description 12
- 238000011269 treatment regimen Methods 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 210000003683 corneal stroma Anatomy 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 230000008929 regeneration Effects 0.000 description 11
- 238000011069 regeneration method Methods 0.000 description 11
- 238000012549 training Methods 0.000 description 11
- 230000004400 visual pathway Effects 0.000 description 11
- 210000000239 visual pathway Anatomy 0.000 description 11
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 10
- 230000001186 cumulative effect Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 201000009487 Amblyopia Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000003560 epithelium corneal Anatomy 0.000 description 9
- 230000004424 eye movement Effects 0.000 description 9
- 238000002647 laser therapy Methods 0.000 description 9
- 238000013532 laser treatment Methods 0.000 description 9
- 210000004498 neuroglial cell Anatomy 0.000 description 9
- 230000005043 peripheral vision Effects 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 210000000411 amacrine cell Anatomy 0.000 description 8
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 8
- 230000002939 deleterious effect Effects 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 210000001747 pupil Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 210000000857 visual cortex Anatomy 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 230000036542 oxidative stress Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 6
- 230000006978 adaptation Effects 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 210000001775 bruch membrane Anatomy 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 230000000750 progressive effect Effects 0.000 description 6
- 239000000790 retinal pigment Substances 0.000 description 6
- 230000004382 visual function Effects 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 5
- 206010025421 Macule Diseases 0.000 description 5
- 201000007737 Retinal degeneration Diseases 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000002287 horizontal cell Anatomy 0.000 description 5
- 239000002831 pharmacologic agent Substances 0.000 description 5
- 239000003504 photosensitizing agent Substances 0.000 description 5
- 208000014733 refractive error Diseases 0.000 description 5
- 210000003994 retinal ganglion cell Anatomy 0.000 description 5
- 239000002151 riboflavin Substances 0.000 description 5
- 235000019192 riboflavin Nutrition 0.000 description 5
- 229960002477 riboflavin Drugs 0.000 description 5
- 230000016776 visual perception Effects 0.000 description 5
- 206010057430 Retinal injury Diseases 0.000 description 4
- 206010045178 Tunnel vision Diseases 0.000 description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000013043 chemical agent Substances 0.000 description 4
- 230000004456 color vision Effects 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000006303 photolysis reaction Methods 0.000 description 4
- 230000008521 reorganization Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 210000003863 superior colliculi Anatomy 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001103 thalamus Anatomy 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 208000021089 Coats disease Diseases 0.000 description 3
- 208000001351 Epiretinal Membrane Diseases 0.000 description 3
- 206010015901 Exudative retinopathy Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 3
- 206010063185 Macular scar Diseases 0.000 description 3
- 208000024080 Myopic macular degeneration Diseases 0.000 description 3
- 208000002367 Retinal Perforations Diseases 0.000 description 3
- 208000008709 Retinal Telangiectasis Diseases 0.000 description 3
- 208000027073 Stargardt disease Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- -1 but not limited to Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 201000008615 cone dystrophy Diseases 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000004300 dark adaptation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000002461 excitatory amino acid Effects 0.000 description 3
- 239000003257 excitatory amino acid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004410 intraocular pressure Effects 0.000 description 3
- 230000004301 light adaptation Effects 0.000 description 3
- 230000004446 light reflex Effects 0.000 description 3
- 208000029233 macular holes Diseases 0.000 description 3
- 201000010230 macular retinal edema Diseases 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 230000004297 night vision Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 230000000649 photocoagulation Effects 0.000 description 3
- 230000008832 photodamage Effects 0.000 description 3
- 210000004694 pigment cell Anatomy 0.000 description 3
- 230000010287 polarization Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 230000004434 saccadic eye movement Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000002739 subcortical effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 206010012667 Diabetic glaucoma Diseases 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 229940122459 Glutamate antagonist Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000032984 Intraoperative Complications Diseases 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- 208000001140 Night Blindness Diseases 0.000 description 2
- 102100036220 PC4 and SFRS1-interacting protein Human genes 0.000 description 2
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 2
- 230000010748 Photoabsorption Effects 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 208000035965 Postoperative Complications Diseases 0.000 description 2
- 206010057765 Procedural complication Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000009246 art therapy Methods 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 210000004227 basal ganglia Anatomy 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000011263 electroactive material Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000005262 ferroelectric liquid crystals (FLCs) Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000003825 glutamate receptor antagonist Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 108010093345 lens epithelium-derived growth factor Proteins 0.000 description 2
- 230000006609 metabolic stress Effects 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002186 photoactivation Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 210000000977 primary visual cortex Anatomy 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 230000001711 saccadic effect Effects 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 206010008795 Chromatopsia Diseases 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 206010052117 Corneal decompensation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010070917 Eccentric fixation Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 229920000106 Liquid crystal polymer Polymers 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 description 1
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010053694 Saccadic eye movement Diseases 0.000 description 1
- CIOAGBVUUVVLOB-NJFSPNSNSA-N Strontium-90 Chemical compound [90Sr] CIOAGBVUUVVLOB-NJFSPNSNSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 229910052775 Thulium Inorganic materials 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ISQINHMJILFLAQ-UHFFFAOYSA-N argon hydrofluoride Chemical compound F.[Ar] ISQINHMJILFLAQ-UHFFFAOYSA-N 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 229950006867 avacincaptad pegol Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229950000025 brolucizumab Drugs 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000004915 chaperone-mediated autophagy Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229940090568 combinations of vitamin Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 201000004573 corneal ectasia Diseases 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 238000002091 elastography Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000004298 light response Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004303 low vision Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004917 microautophagy Effects 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000023105 myelination Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000035771 neuroregeneration Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 235000020956 nicotinamide riboside Nutrition 0.000 description 1
- 239000011618 nicotinamide riboside Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 201000003841 peripheral retinal degeneration Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001601 polyetherimide Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004647 pro-inflammatory pathway Effects 0.000 description 1
- 230000006482 proangiogenic pathway Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002522 prostaglandin receptor stimulating agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004478 pupil constriction Effects 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 230000006010 pyroptosis Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 230000004256 retinal image Effects 0.000 description 1
- 230000004286 retinal pathology Effects 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 102000000568 rho-Associated Kinases Human genes 0.000 description 1
- 108010041788 rho-Associated Kinases Proteins 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000001149 thermolysis Methods 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000004412 visual outcomes Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229950001212 volociximab Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/145—Corneal inlays, onlays, or lenses for refractive correction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/16—Intraocular lenses
- A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
- A61F2/1648—Multipart lenses
- A61F2/1651—Multipart lenses comprising a telescope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00863—Retina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00897—Scanning mechanisms or algorithms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/0053—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in optical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H5/00—Exercisers for the eyes
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C2202/00—Generic optical aspects applicable to one or more of the subgroups of G02C7/00
- G02C2202/10—Optical elements and systems for visual disorders other than refractive errors, low vision
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/119,617 | 2020-12-11 | ||
| PCT/US2020/064620 WO2022125116A1 (fr) | 2020-12-11 | 2020-12-11 | Dispositifs et procédés destinés à une nouvelle modification de distribution d'éclairement énergétique rétinienne afin d'améliorer et de restaurer la vision sans produire de vitrification de la cornée |
| US17/119,617 US11974945B2 (en) | 2017-08-31 | 2020-12-11 | Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020480841A1 true AU2020480841A1 (en) | 2023-07-27 |
| AU2020480841A9 AU2020480841A9 (en) | 2024-05-09 |
Family
ID=81973868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020480841A Pending AU2020480841A1 (en) | 2020-12-11 | 2020-12-11 | Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4259054A1 (fr) |
| JP (1) | JP2024504245A (fr) |
| CN (1) | CN116829109A (fr) |
| AU (1) | AU2020480841A1 (fr) |
| CA (1) | CA3200780A1 (fr) |
| WO (1) | WO2022125116A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60042155D1 (de) * | 1999-03-24 | 2009-06-18 | Second Sight Medical Prod Inc | Retinale farbprothese zur wiederherstellung des farbsehens |
| US8486055B2 (en) * | 2007-06-26 | 2013-07-16 | Bausch & Lomb Incorporated | Method for modifying the refractive index of ocular tissues |
| US20190060056A1 (en) * | 2017-08-31 | 2019-02-28 | Olivia Serdarevic | Devices and Methods for Novel Retinal Irradiance Distribution Modification to Improve and Restore Vision |
| EP3664747A4 (fr) * | 2017-09-14 | 2021-04-28 | Board Of Trustees Of The University Of Illinois | Dispositifs, systèmes et méthodes de restauration de la vision |
| US10175490B1 (en) * | 2017-12-20 | 2019-01-08 | Aperture In Motion, LLC | Light control devices and methods for regional variation of visual information and sampling |
-
2020
- 2020-12-11 EP EP20965294.0A patent/EP4259054A1/fr active Pending
- 2020-12-11 JP JP2023535559A patent/JP2024504245A/ja active Pending
- 2020-12-11 CA CA3200780A patent/CA3200780A1/fr active Pending
- 2020-12-11 AU AU2020480841A patent/AU2020480841A1/en active Pending
- 2020-12-11 CN CN202080108398.4A patent/CN116829109A/zh active Pending
- 2020-12-11 WO PCT/US2020/064620 patent/WO2022125116A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024504245A (ja) | 2024-01-31 |
| AU2020480841A9 (en) | 2024-05-09 |
| CA3200780A1 (fr) | 2022-06-16 |
| EP4259054A1 (fr) | 2023-10-18 |
| WO2022125116A1 (fr) | 2022-06-16 |
| CN116829109A (zh) | 2023-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11766354B2 (en) | Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification | |
| McDonald et al. | Excimer laser ablation human eye | |
| TW453871B (en) | Device for the treatment of macular degeneration and other eye disorders | |
| US10386646B1 (en) | Light control devices and methods for regional variation of visual information and sampling | |
| US20040030269A1 (en) | Method and apparatus for the correction of presbyopia using high intensity focused ultrasound | |
| US20020049450A1 (en) | Correction of presbyopia, other refractive errors and cataract retardation | |
| US20240074903A1 (en) | Laser System and Method for Correction of Induced Astigmatism | |
| US11974945B2 (en) | Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification | |
| WO2017039488A1 (fr) | Méthode d'opérations chirurgicales ophtalmologiques utilisant un autogreffon | |
| AU2020480841A1 (en) | Devices and methods for novel retinal irradiance distribution modification to improve and restore vision without producing corneal vitrification | |
| US20210311324A1 (en) | Device and method for creating an aperture diaphragm in an intraocular lens | |
| RU2819741C1 (ru) | Способ хирургического лечения катаракты или факосклероза посредством фемтосекундного лазера (ФСЛ) с профилактикой интраоперационного миоза | |
| RU2773005C2 (ru) | Комбинированный способ восстановления зрительных функций у пациентов с резидуальной миопией после фемтосекундной экстракции лентикулы через малый доступ | |
| Ting et al. | Improvement in accommodation and dynamic range of focus after laser scleral microporation: A potential treatment for presbyopia. Transl Vis Sci Technol. 2022; 11 (12): 2 | |
| RU2314072C1 (ru) | Способ профилактики развития диабетического макулярного отека у больных сахарным диабетом ii типа | |
| Isroilova et al. | AN INNOVATIVE THERAPEUTIC TOOL IN BIOPHYSICS IN THE FIELD OF MEDICINE (LASIK) | |
| Nanavaty et al. | Phakic IOL implantation versus clear lens extraction in highly myopic eyes | |
| Shugar | Laser iridoplasty for congenital ectopic pupils | |
| Borovic-Pavlovschi | Phacoemulsification of the crystallinelens with intracapsular implant for the correction of high myopia | |
| Fyodorov | history in the lI1aking | |
| CZ9795A3 (cs) | Způsob korekčního neinvasivního zlepšení vidění okem stiženým částečnou degenerací sítnice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |